Quick Answer
Valion Bio, Inc. reported Total Revenue of $780.0 thousand for fiscal year 2024.
Valion Bio, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2024 | $780.0K | -33.7% |
| 2023 | $1.18M | -36.1% |
| 2022 | $1.84M | +46.4% |
| 2021 | $1.26M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $146.0K | +15.9% | +69.8% |
| June 30, 2025 | $86.0K | -38.6% | +22.9% |
| March 31, 2025 | $70.0K | -79.0% | -44.4% |
| September 30, 2024 | $126.0K | -55.3% | -10.0% |
| June 30, 2024 | $140.0K | -13.0% | -58.1% |
| March 31, 2024 | $334.0K | -11.2% | +18.4% |
| September 30, 2023 | $282.0K | -40.9% | +75.2% |
| June 30, 2023 | $161.0K | -69.5% | -57.2% |
- Valion Bio, Inc. showed a decrease of -33.7% in Total Revenue compared to the prior fiscal year.
- Over the 2021–2024 period, Valion Bio, Inc.’s total revenue has declined by 37.9% (from $1.26 million to $780.0 thousand).
- The most recent figure is from Valion Bio, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 21, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: